Neuphoria Therapeutics Inc. Stock Analysis & AI Score
Neuphoria Therapeutics Inc. (NEUP) has an ST Score of 41.8 (C), driven by its Financial Strength (A+) and held back by its Momentum (D+). Analysts rate it Buy with a $7.00 price target (+91.8% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Neuphoria Therapeutics Inc. (NEUP) has an ST Score of 41.8 (C), driven by its Financial Strength (A+) and held back by its Momentum (D+). Analysts rate it Buy with a $7.00 price target (+91.8% upside).
- Strongest
- Financial StrengthA+
- Weakest
- MomentumD+
All factor grades
- Financial StrengthA+
- ForecastB
- ValuationC
- ProfitabilityC-
- GrowthC-
- MomentumD+
- Piotroski1/9
Contact
NEUP stock: frequently asked questions
What is NEUP's ST Score?
Neuphoria Therapeutics Inc. (NEUP) has an ST Score of 41.8 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is NEUP a buy, hold, or sell?
Analysts rate NEUP a Buy, with a price target of $7.00 (+91.8% vs the current price). Our ST Score grades it C (41.8/100). The ST Score is a data-driven signal, not a recommendation.
What are NEUP's factor grades?
Valuation C, Profitability C-, Financial Strength A+, Momentum D+, Growth C-, Forecast B.
What is NEUP's valuation grade?
Neuphoria Therapeutics Inc. (NEUP) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is NEUP's growth grade?
Neuphoria Therapeutics Inc. (NEUP) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is NEUP's profitability grade?
Neuphoria Therapeutics Inc. (NEUP) earns a profitability grade of C-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is NEUP's financial strength grade?
Neuphoria Therapeutics Inc. (NEUP) earns a financial strength grade of A+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for NEUP?
The average analyst price target for Neuphoria Therapeutics Inc. (NEUP) is $7.00 from 2 analysts, which is +91.8% versus the recent price of $3.65.
What is NEUP's Piotroski score?
Neuphoria Therapeutics Inc. (NEUP) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.